tbuckley/cabot-search huggingface dataset:
Biweekly treatment with bevacizumab (BV) as 2<sup>nd</sup> line chemotherapy in patients with metastatic colorectal cancer
Authors: G. F. Samelis, A. Areovimata, D. Adrachta, A. Palazi, V. Papagianni
Journal: Journal of Clinical Oncology (2006)

13561 Background: Bevacizumab (BV), a monoclonal antibody directed against vascular endothelial growth factor, provides a survival advantage (15.6 to 20.3 months) when added to first-line chemotherapy for metastatic colorectal cancer (metastatic CRC). Only a few trials have been conducted using BV as 2 nd line chemotherapy. Methods: Sixteen patients with metastatic CRC refractory to first-line chemotherapy (oxaliplatin or irinotecan-based regimen) were enrolled. All patients, after progressing in first-line treatment, received the following regimen: BV: 5 mg/Kg* in 1000ml water for injection in 90min IV infusion plus irinotecan 125mg/m 2 IV in 500ml NIS in 60min plus folinic acid 30mg/m 2 and 5-fluorouracil 500mg/m 2 IV bolus infusion. The schedule was repeated every 2 weeks. Fourteen men and 2 women entered the study with PS 0–1, median age of 66 years (range: 48–85). 11 patients (68.7%) had liver metastases, 3 patients (18.75%) had lung metastases and 4 patients (25%) had local tumor recurrence. All 16 patients were eligible for the study and received in total 174 (mean 10.8, range: 6–20) cycles. Six out of 16 patients (12.5%) had more than 2 metastatic sites (liver and local recurrence). Results: Six patients had partial responses (PRs) (37.5%), 4 patients had stable disease (SD) (25%) and the rest of the patients progressed (37.5%). The time to progression (TTP) was 6.4 months (range: 4–8), and the median survival was 9 (range: 5–12) months. The toxicity was mild and no toxic death was reported. Grade II toxicities were the following: epistaxis 4 patients (25%), anaemia 5 patients (31%), leukopenia 3 patients (18.7%), granulocytopenia 2 patients (12.5%) and 1 patient developed jaundice due to bile-duct obstruction. Conclusions: The bi-weekly administration of BV, irinotecan, leucovorin and 5-fluororacil is acceptable as 2 nd line treatment in patients with metastatic CRC, with an overall response rate (PRs) of 37.5%, and SD of 25%. The TTP and survival were 6.4 and 9 months respectively. The study is ongoing and we expect to enrol more patients. No significant financial relationships to disclose.
Minimum unit pricing for alcohol in Scotland
Authors: John D Mooney, Eric Carlin
Journal: BMJ (2019)

In 2018, after six years of legal challenges by global alcohol producers, Scotland became the first country in the world to implement a national MUP policy, setting a limit of 50p ($0.62; €0.56) per unit (10 mL/8 g alcohol) below which alcohol cannot be sold. NHS Health Scotland are leading a comprehensive evaluation of the impact in advance of a 2023 review of the policy, as specified in a sunset clause in the legislation.
The main analysis found that the introduction of MUP was followed by a price increase of 6.4p per gram of alcohol (7.9%) and a reduction of 9.5 g (95% confidence interval 5.1 to 13.9) in off-trade alcohol purchased for each adult per household. Immediate reductions were most notable for beer, spirits, and cider, including own brand spirits and high strength white ciders. The 9.5 g reduction overall is equivalent to slightly more than one unit of alcohol—roughly half a pint of beer, a third of a can of strong cider, or one measure of spirits.
Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum
Authors: Lucia Nappi, Marisa Thi, Amy Lum, David Huntsman, Bernie J. Eigl, Christopher Martin, Brock O’Neil, Benjamin L. Maughan, Kim Chi, Alan So, Peter C. Black, Martin Gleave, Alex W. Wyatt, Jean Michel Lavoie, Daniel Khalaf, Robert Bell, Siamak Daneshmand, Robert J. Hamilton, Ricardo R.N. Leao, Craig Nichols, Christian Kollmannsberger
Journal: Journal of Clinical Oncology (2019)

PURPOSE Our objective was to evaluate operating characteristics, particularly specificity and positive predictive value (PPV), by mapping plasma miR371 expression to actual clinical events in patients with a history of germ cell tumor. PATIENTS AND METHODS One hundred eleven male patients with a history of or newly diagnosed germ cell tumors were evaluable. Biospecimens obtained before confirmed clinical events were analyzed for miR371 expression with blinding of providers and laboratory personnel to analytic results or clinical status, respectively. Cases (patients with clinically confirmed active germ cell malignancy [aGCM]) and controls (patients with no clinically confirmed aGCM) were assigned over the course of the management. Patients were assigned risk status (high, low, or moderate) based on the composite clinical picture at time points in management. RESULTS Considering all cases and controls and results of prospectively obtained biosamples analyzed for miR371 expression, 46 (35%) of 132 samples had clinically confirmed aGCM over the course of management; 44 (96%) of these 46 patients had plasma miR371 expression (true positives) with no false positives. Two (4%) of 46 patients had no miRNA expression despite pathologic confirmation of aGCM (false negatives). Plasma miR371 expression in confirmed aGCM had a specificity, sensitivity, positive predictive value, and negative predictive value of 100%, 96%, 100%, and 98%, respectively. Interpretation of sensitivity and negative predictive value is limited by modest follow-up. Specificity and sensitivity were 100% and 98%, 100% and 92%, and 100% and 97% in the low-, moderate-, and high-risk groups, respectively, with a median follow-up time of 15 months. CONCLUSION Plasma miR371 expression predicts aGCM with high specificity and positive predictive value. Although other operating characteristics of miR371 await longer follow-up for more complete definition, the findings of a highly specific liquid biopsy strongly support moving forward with large-scale, real-world clinical trials to further define full operating characteristics and to identify clinical utility and areas of patient benefit.
Type 1 Diabetes Accelerates Progression of Coronary Artery Calcium Over the Menopausal Transition: The CACTI Study
Authors: Amena Keshawarz, Laura Pyle, Amy Alman, Caprice Sassano, Elizabeth Westfeldt, Rachel Sippl, Janet Snell-Bergeon
Journal: Diabetes Care (2019)

OBJECTIVE Type 1 diabetes is associated with a higher risk of cardiovascular disease (CVD) in women. Although menopause increases risk of CVD, it is uncertain how menopause affects risk of CVD in women with type 1 diabetes. We examined whether risk of CVD changes differentially in women with and those without type 1 diabetes over the transition through menopause. RESEARCH DESIGN AND METHODS Premenopausal women with type 1 diabetes (n = 311) and premenopausal women without diabetes (n = 325) enrolled in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study and attended up to four study visits over 18 years. Coronary artery calcium (CAC) volume was measured from computed tomography scans obtained at each visit. Longitudinal repeated-measures modeling estimated the effect of diabetes on CAC volume over time and the effect of menopause on the diabetes-CAC relationship. RESULTS CAC volume was higher at baseline and increased more over time in women with type 1 diabetes than in women without diabetes. A significant diabetes-by-menopause interaction was found (P &amp;lt; 0.0001): postmenopausal women with type 1 diabetes had significantly higher CAC volumes than premenopausal women (5.14 ± 0.30 vs. 2.91 ± 0.18 mm3), while there was no difference in women without diabetes (1.78 ± 0.26 vs. 1.78 ± 0.17 mm3). This interaction remained significant after adjusting for CVD risk factors. CONCLUSIONS Type 1 diabetes was associated with higher CAC volume and accelerated progression of CAC over time. Menopause increased CAC progression more in women with diabetes than in women without diabetes independent of age and other CVD risk factors known to worsen with menopause.
TCT-681 In-Hospital and Short-Term TAVR Outcomes in Patients With and Without Unrevascularized Coronary Artery Disease
Authors: Barbora Zvarova, Zaid Almarzooq, Marc Pelletier, Tsuyoshi Kaneko, Piotr Sobieszczyk, Pinak Shah, Natalia Berry
Journal: Journal of the American College of Cardiology (2019)
Strong COX-2 overexpression in breast and prostate cancer - a potential therapeutic target.
Authors: Peter J. Wild, Leoni A. Kunz-Schughart, Frauke Bataille, Ronald Simon, Guido Sauter, Michael Mihatsch, Arndt Hartmann
Journal: Cancer Research (2004)

3059  Aims: Cyclooxygenase-2 (COX-2) is overexpressed in many different malignant tumors, and levels of overexpression have been shown to correlate with invasiveness and prognosis. The aim of the present high-throughput tissue microarray (TMA) study was to investigate wether COX-2 expression is associated with clinical, pathologic and molecular parameters in breast and prostate cancer. Methods: Tissue microarrays (TMA) were used to immunohistochemically analyze COX-2 expression in 2197 breast cancers. Additionally, a TMA was constructed containing 78 high-grade prostatic intraepithelial neoplasia (PIN III), 191 clinically localized prostate cancers, 120 hormone-refractory local recurrences, 78 distant metastases, and 65 benign prostatic hyperplasias (BPH) as controls. A monoclonal mouse antibody (Cayman; working concentration 5 μg) was used after heat-induced antigen retrieval. COX-2 expression was scored semiquantitatively (0-3+). Results: In breast cancer, moderate (2+) and strong (3+) overexpression of COX-2 was detected in 39.6% and 9%, respectively. Strong COX-2 expression was significantly correlated with higher tumor stage (p=0.001) and BRE grade (p 10%; p
TCT-248 Coronary Artery Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention: Epidemiology, Mechanisms, Management, and Outcomes
Authors: Lorenzo Azzalini, Mohamed Ayoub, Soledad Ojeda, Carlo Zivelonghi, Alessio La Manna, Barbara Bellini, Adrián Lostalo, Aurora Luque, Giuseppe Venuti, Matteo Montorfano, Pierfrancesco Agostoni, Manuel Pan, Mauro Carlino, Kambis Mashayekhi
Journal: Journal of the American College of Cardiology (2019)
TCT-246 The Efficacy of Modified Jailed Balloon Technique for Bifurcation Lesions in Long-Term Follow-Up
Authors: Koki Shishido, Noriaki Moriyama, Takahiro Hayashi, Shohei Yokota, Hirokazu Miyashita, Tomoki Ochiai, Kazuki Tobita, Futoshi Yamanaka, Shingo Mizuno, Yutaka Tanaka, Saeko Takahashi, Shigeru Saito
Journal: Journal of the American College of Cardiology (2019)
Reply to A.S. Garden
Authors: Daniel J. Ma, Katharine A. Price, Eric J. Moore, Samir H. Patel, Michael L. Hinni, Joaquin J. Garcia, Darlene E. Graner, Michelle Neben-Wittich, Yolanda I. Garces, Ashish V. Chintakuntlawar, Daniel L. Price, Kathryn M. Van Abel, Jan L. Kasperbauer, Jeffrey R. Janus, Mark Waddle, Robert C. Miller, Satomi Shiraishi, Robert W. Mutter, Kimberly S. Corbin, Sean S. Park, Robert L. Foote
Journal: Journal of Clinical Oncology (2019)

We thank A
TCT-326 Diagnostic Performance of Angiography-Based Quantitative Flow Ratio With Respect to Fractional Flow Reserve Derived From Computed Tomography Angiography: Insight From the SYNTAX III Trial
Authors: Kuniaki Takahashi, Norihiro Kogame, Mariusz Tomaniak, Ply Chichareon, Chun-Chin Chang, Rodrigo Modolo, Masafumi Ono, Hideyuki Kawashima, Johan Reiber, Daniele Andreini, Torsten Doenst, Patrick Serruys, Yoshinobu Onuma
Journal: Journal of the American College of Cardiology (2019)
TCT-108 Physiologic Characteristics and Clinical Outcomes of Patients With Discordance Between Fractional Flow Reserve and Instantaneous Wave-Free Ratio
Authors: Seung Hun Lee, Ki Hong Choi, Joo Myung Lee, Doyeon Hwang, Tae-Min Rhee, Jonghanne Park, Hyun Kuk Kim, Yun-Kyeong Cho, Hyuck-Jun Yoon, Jinhyoung Park, Young Bin Song, Joo-Yong Hahn, Jae-Jin Kwak, Joon-Hyung Doh, Chang-Wook Nam, Eun-Seok Shin, Seung-Ho Hur, Bon-Kwon Koo
Journal: Journal of the American College of Cardiology (2019)
TCT-828 Quantitative Validation of the Coronary-Angioscopic Yellow Plaque by Lipid Core Burden Index Assessed by Intra-Coronary Near-Infrared Spectroscopy
Authors: Takashi Omatsu, Tomoaki Kobayashi, Yohei Sotomi, Yuma Hamanaka, Yasunori Ueda, Yoshiharu Higuchi
Journal: Journal of the American College of Cardiology (2019)
Risk Factors Associated With Food Insecurity in the Medicare Population
Authors: Jeanne M. Madden, Prathwish S. Shetty, Fang Zhang, Becky A. Briesacher, Dennis Ross-Degnan, Stephen B. Soumerai, Alison A. Galbraith
Journal: JAMA Internal Medicine (2019)

Risk Factors Associated With Food Insecurity in the Medicare PopulationFood insecurity is defined as the inability to obtain adequate food for explicitly financial reasons.Associations between food insecurity and worse health outcomes have been attributed to insufficient nutritional intake, trade-offs between food and medical treatment, and functional impairments. 1Medicare enrollees, who are 65 years or older or who have long-term disabilities, are especially vulnerable to food insecurity.We present detailed national estimates of food insecurity prevalence within the Medicare population.Methods | Data are from the 2016 Medicare Current Beneficiary Survey, administered by the US Centers for Medicare & Medicaid Services with interviews between July 25, 2016, and August 31, 2017.The Medicare Current Beneficiary Survey uses the 6-item version of the US Department of Agriculture's food security questionnaire, 2 which references respondent experiences from the previous 12 months and asks if their food had ever run out, if they had no money to get more, or if they were unable to eat balanced meals, cut meal size or skipped meals, ate less than they ought, or were hungry because of insufficient money.Using an established algorithm, 2 our outcome designates an individual with any 2 affirmative responses as food insecure.Covariates included previously established predictors of food insecurity or difficulties affording health care. 3-5All health-related covariates were self-reported.The Centers for Medicare & Medicaid Services administrative data contributed to demographic covariates, supplemental insurance type, and Accountable Care Organization assignment.We restricted analysis to 9674 community-dwellers with continuous 2016 Medicare enrollment who completed the food security interview, using Medicare Current Beneficiary Survey sampling weights to represent a national population of 50 685 869 community-dwelling Medicare enrollees.We separately analyzed respondents as younger than 65 years and 65 years and older.This study was approved by the Harvard Pilgrim Health Care Institutional Review Board with a waiver of informed consent.Results | We found that 38.3% (95% CI, 34.5%-42.1%) of enrollees younger than 65 reported food insecurity (Table 1).Other characteristics of social and clinical vulnerability (eg, income less than $15k per year, 4 or more chronic conditions,
Reproducing the molecular subclassification of peripheral T-cell lymphoma–NOS by immunohistochemistry
Authors: Catalina Amador, Timothy C. Greiner, Tayla B. Heavican, Lynette M. Smith, Karen Tatiana Galvis, Waseem Lone, Alyssa Bouska, Francesco D’Amore, Martin Bjerregaard Pedersen, Stefano Pileri, Claudio Agostinelli, Andrew L. Feldman, Andreas Rosenwald, German Ott, Anja Mottok, Kerry J. Savage, Laurence de Leval, Philippe Gaulard, Soon Thye Lim, Choon Kiat Ong, Sarah L. Ondrejka, Joo Song, Elias Campo, Elaine S. Jaffe, Louis M. Staudt, Lisa M. Rimsza, Julie Vose, Dennis D. Weisenburger, Wing C. Chan, Javeed Iqbal
Journal: Blood (2019)
Inhibition of Btk Does Not Block Platelet Activation By GPVI: Studies with Ibrunitib, Acalabrutinib and Patients with X-Linked Agammaglobulinaemia
Authors: Phillip Lr Nicolson, Stephanie Watson, Craig E Hughes, Alexander T Hardy, Callum N Watson, Samantha J Montague, Michael G Tomlinson, Guy Pratt, Steve P Watson
Journal: Blood (2017)
Sequential Azacitidine (Aza) and Lenalidomide (Len) for Patients (Pts) with Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML): Clinical Results and Predictive Modeling Using Computational Analysis and Serial Genomics
Authors: Brett M. Stevens, Amanda Winters, Jonathan A Gutman, Aaron Fullerton, Gregory Hemenway, Nicholas Miltgen, Qi Wei, Taher Abbasi, Shireen Vali, Neeraj Kumar Singh, Leylah M. Drusbosky, Chris R. Cogle, Andrew Hammes, Craig T. Jordan, Daniel A. Pollyea
Journal: Blood (2017)
Letter by Hüttemann et al Regarding Article, “Ndufs2, a Core Subunit of Mitochondrial Complex I, Is Essential for Acute Oxygen-Sensing and Hypoxic Pulmonary Vasoconstriction”
Authors: Maik Hüttemann, Natascha Sommer, Norbert Weissmann, Lawrence I. Grossman
Journal: Circulation Research (2019)
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Authors: Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, Simon Chowdhury, Andrea J Pereira de Santana Gomes, Byung Ha Chung, Mustafa Özgüroğlu, Álvaro Juárez Soto, Axel S Merseburger, Hirotsugu Uemura, Dingwei Ye, Robert Given, David Cella, Ethan Basch, Branko Miladinovic, Lindsay Dearden, Kris Deprince, Vahid Naini, Angela Lopez-Gitlitz, Kim N Chi
Journal: The Lancet Oncology (2019)
TCT-715 Anatomic Evaluation of Balloon-Expandable Transcatheter Aortic Valve Replacement: Computed Tomography Insights for Hypo-Attenuating Leaflet Thickening
Authors: Miho Fukui, Liang Tang, John Lesser, Hiroki Niikura, Mariana Nunes, Marcus Burns, Lynelle Schneider, B. Kelly Han, Santiago Garcia, Mario Goessl, Paul Sorajja, Joao Cavalcante
Journal: Journal of the American College of Cardiology (2019)
TCT-831 Identification of High-Risk Plaques by Coronary Angiography: Confirmation of Computational Fluid Dynamics by Optical Coherence Tomography
Authors: Naotaka Okamoto, Yuliya Vengrenyuk, Valentin Fuster, Keisuke Yasumura, Habib Samady, Usman Baber, Nitin Barman, Joseph Sweeny, Prakash Krishnan, Roxana Mehran, Samin Sharma, Jagat Narula, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2019)
TCT-295 Prognosis of Percutaneous Coronary Intervention With Very Long Stents Implantation in Real Clinical Practice
Authors: José Abellán-Huerta, Martin Negreira-Caamaño, Alfonso Jurado-Román, María López-Lluva, Ignacio Sanchez-Perez, Pedro Pérez-Díaz, Raquel Frías, Juan Antonio Requena, Ramon Maseda, Fernando Lozano
Journal: Journal of the American College of Cardiology (2019)
TCT-375 Canadian WATCHMAN Registry for Percutaneous Left Atrial Appendage Closure
Authors: Jacqueline Saw, Thomas Gilhofer, Colin Pearce, Malek Kass, Carlos Morillo, Stephan Wardell, Jean-Michel Paradis, Jay Thakkar, Peter Fahmy, Naomi Uchida, Gilles O'Hara
Journal: Journal of the American College of Cardiology (2019)
Abstract 14244: What Do U.S. Physicians Think About Lipid-Lowering Therapy and the Guidelines? Results From a National Survey in the Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) Registry
Authors: Christopher P Cannon, James A de Lemos, Robert S Rosenson, Christie M Ballantyne, Juan M Maya, Katherine E Mues, Yuyin Liu, Deepak L Bhatt, Mikhail N Kosiborod
Journal: Circulation (2018)

Background: Recent guidelines on management of cholesterol have shifted the emphasis from titrating therapies based on low-density lipoprotein cholesterol (LDL-C) levels to intensity of statin ther...
Abstract 15284: Discharge Non-Prescription of Statins and Renin-Angiotensin-Aldosterone Inhibitors Associated With Two-Year Mortality in Japanese Percutaneous Coronary Intervention Patients: Report From a Prospective Multicenter Registry
Authors: Mitsuaki Sawano, Shun Kohsaka, Ikuko Ueda, Hiroyuki Miyata, Koichiro Sueyoshi, Yohei Numasawa, Masahiro Suzuki, Shigetaka Noma, Kentaro Hayashida, Shinsuke Yuasa, Keiichi Fukuda
Journal: Circulation (2017)

Introduction: Reduction in the number of repeat revascularizations and long-term mortality after PCI is the ultimate goal for both the treating physician and the patient. In our current study, we s...
Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study
Authors: Niels Verburg, Thomas Koopman, Maqsood M Yaqub, Otto S Hoekstra, Adriaan A Lammertsma, Frederik Barkhof, Petra J W Pouwels, Jaap C Reijneveld, Jan J Heimans, Annemarie J M Rozemuller, Anne M E Bruynzeel, Frank Lagerwaard, William P Vandertop, Ronald Boellaard, Pieter Wesseling, Philip C de Witt Hamer
Journal: Neuro-Oncology (2019)

Abstract Background Surgical resection and irradiation of diffuse glioma are guided by standard MRI: T2/fluid attenuated inversion recovery (FLAIR)–weighted MRI for non-enhancing and T1-weighted gadolinium-enhanced (T1G) MRI for enhancing gliomas. Amino acid PET has been suggested as the new standard. Imaging combinations may improve standard MRI and amino acid PET. The aim of the study was to determine the accuracy of imaging combinations to detect glioma infiltration. Methods We included 20 consecutive adults with newly diagnosed non-enhancing glioma (7 diffuse astrocytomas, isocitrate dehydrogenase [IDH] mutant; 1 oligodendroglioma, IDH mutant and 1p/19q codeleted; 1 glioblastoma IDH wildtype) or enhancing glioma (glioblastoma, 9 IDH wildtype and 2 IDH mutant). Standardized preoperative imaging (T1-, T2-, FLAIR-weighted, and T1G MRI, perfusion and diffusion MRI, MR spectroscopy and O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) PET) was co-localized with multiregion stereotactic biopsies preceding resection. Tumor presence in the biopsies was assessed by 2 neuropathologists. Diagnostic accuracy was determined using receiver operating characteristic analysis. Results A total of 174 biopsies were obtained (63 from 9 non-enhancing and 111 from 11 enhancing gliomas), of which 129 contained tumor (50 from non-enhancing and 79 from enhancing gliomas). In enhancing gliomas, the combination of apparent diffusion coefficient (ADC) with [18F]FET PET (area under the curve [AUC], 95% CI: 0.89, 0.79‒0.99) detected tumor better than T1G MRI (0.56, 0.39‒0.72; P &amp;lt; 0.001) and [18F]FET PET (0.76, 0.66‒0.86; P = 0.001). In non-enhancing gliomas, no imaging combination detected tumor significantly better than standard MRI. FLAIR-weighted MRI had an AUC of 0.81 (0.65–0.98) compared with 0.69 (0.56–0.81; P = 0.019) for [18F]FET PET. Conclusion Combining ADC and [18F]FET PET detects glioma infiltration better than standard MRI and [18F]FET PET in enhancing gliomas, potentially enabling better guidance of local therapy.